Cellebrite DI (NASDAQ:CLBT) Stock Price Up 7.1% – Should You Buy?

Cellebrite DI Ltd. (NASDAQ:CLBT)’s stock price traded up 7.1% during trading on Thursday . The stock traded as high as $15.15 and last traded at $15.1670. 1,096,592 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 1,895,732 shares. The stock had previously closed at $14.16.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Bank of America lifted their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Lake Street Capital boosted their price objective on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Stock Performance

The stock has a fifty day moving average of $15.74 and a 200-day moving average of $16.96. The company has a market cap of $3.65 billion, a PE ratio of 49.15, a PEG ratio of 2.11 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. During the same period last year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds have recently modified their holdings of the business. Y.D. More Investments Ltd lifted its holdings in Cellebrite DI by 76.2% during the second quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock worth $7,065,000 after buying an additional 191,020 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Cellebrite DI by 40.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after acquiring an additional 103,568 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Cellebrite DI in the 2nd quarter worth $657,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth $19,457,000. Finally, Moody National Bank Trust Division bought a new stake in Cellebrite DI during the third quarter valued at about $2,670,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.